The Latest Breaking News from Merck

Dow Jones futures dropped after Monday's stock market rally ahead of the Federal Reserve's two-day policy meeting.

The Dow Jones Industrial Average fell Monday, as the 10-year Treasury yield surged to hit an 11-year high ahead of the Fed meeting.

Are you spooked because the S&P 500 is off 16.26% going into Thursday? If you are, then check out Hartford Equity Income Fund. It's beating the bogey.

Persistent rate hikes by the Fed and rising odds of a recession have aggravated market turbulence and led investors to seek refuge in defensive sectors such as healthcare. Defensive stocks tend to perform well in declining markets due to the steady demand for their products. Hence, consistent dividend-yielding drug stocks…

Akero Therapeutics (NASDAQ:AKRO) revealed topline data from HARMONY, a 24-week Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin (EFX) in patients with pre-cirrhotic nonalcoholic steatohepatitis (NASH), the study met its primary endpoint for both the 50mg and 28mg EFX dose groups. Akero Therapeutics shares…

A gamble could pay off for Merck stock after blockbuster Keytruda nearly doubled the five-year survival rate for some lung cancer patients.

The U.S. Food and Drug Administration (FDA) has approved Spectrum Pharmaceuticals’ (NASDAQ:SPPI) lead asset ROLVEDON (eflapegrastim-xnst) injection to decrease the incidence of infection, as manifested by febrile neutropenia. Spectrum Pharmaceuticals shares traded as high as 3.17 percent, in a range of $1.21 to $1.30 on day volume of 6.8 million…

Persistent economic turbulence and an uncertain outlook have led investors to prioritize steady income generation from their investments. Hence, fundamentally sound dividend yielders with a solid track record and potential for perpetual growth Merck (MRK), Abbott (ABT), Cigna (CI), Energy Transfer (ET), and Kronos (KRO) could be permanent additions to…

The Dow Jones moved higher into the close while blue chip stocks gained in heavy volume. Defensive sectors led the upside on Thursday.

Merck's rumored takeover of cancer-focused biotech Seagen has stalled on price, according to a report Friday that sent SGEN stock tumbling.

CNBC The Aviation Sector Is Slammed By Sky-High Rents